The 2009 list of the top 20 pharmaceutical companies, ranked by IMS Health according to global prescription drug sales for the 12 months up to September 2009, shows that Teva, Novo Nordisk and Boehringer Ingelheim scored better in percent change than Big Pharma in those months.
IMS Health Top 20 pharmaceutical companies 2009
Home/Pharma News
|
Posted 23/04/2010
0
Post your comment
The data below does not take into account the large acquisitions by Pfizer and Merck, of Wyeth and Schering-Plough respectively, which were completed after September 2009.
| Company Sales | (billion US$) | % change |
| 1. Pfizer | 41.7 | (0.8) |
| 2. Novartis | 36.7 | 7.0 |
| 3. Sanofi-aventis | 35.1 | 3.3 |
| 4. GlaxoSmithKline | 34.3 | (3.4) |
| 5. AstraZeneca | 33.2 | 7.8 |
| 6. Roche | 31.3 | 8.6 |
| 7. Johnson & Johnson | 26.9 | (6.6) |
| 8. Merck & Co | 25.0 | (4.1) |
| 9. Eli Lilly | 19.6 | 8.3 |
| 10. Abbott | 19.4 | 5.5 |
| 11. Teva | 15.7 | 12.3 |
| 12. Bayer | 15.4 | 3.9 |
| 13. Wyeth | 14.8 | (2.3) |
| 14. Amgen | 14.8 | (3.1) |
| 15. Boehringer Ingelheim | 14.6 | 10.4 |
| 16. Takeda | 14.4 | 2.1 |
| 17. Bristol-Myers | 14.2 | 5.8 |
| 18. Schering-Plough | 13.1 | 4..3 |
| 19. Daiichi Sankyo | 8.5 | 3.1 |
| 20. Novo Nordisk | 8.2 | 11.6 |
References:
IMS Health
FACTBOX-The 20 largest pharmaceutical companies. Reuters. 2010 March 26.
Guidelines
New guidance for biologicals in Pakistan and Hong Kong’s independent drug regulatory authority
Canada poised to remove requirement for Phase III trials for biosimilars
Policies & Legislation
Argentina streamlines drug approval process
ANVISA tackles 24-month backlog in biologicals post-registration petitions
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Formycon signs new aflibercept biosimilar pacts and launches ranivisio in Europe
Bio-Thera and Stada expand biosimilars alliance to include tocilizumab
Global partnerships for biosimilar commercialization announced
New denosumab and ustekinumab biosimilar launches in US, Canada and Japan
Related content
Formycon signs new aflibercept biosimilar pacts and launches ranivisio in Europe
Home/Pharma News Posted 13/11/2025
Bio-Thera and Stada expand biosimilars alliance to include tocilizumab
Home/Pharma News Posted 20/10/2025
New denosumab and ustekinumab biosimilar launches in US, Canada and Japan
Home/Pharma News Posted 10/07/2025
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment